Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen transitions to Genelux from Rani Therapeutics, where he served as General Counsel since September 2021. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-appointment-eric-groen-general?utm_source=openai))
Prior to his tenure at Rani Therapeutics, Groen spent nearly two decades at Amgen, holding various domestic and international legal positions. His roles included leading legal teams responsible for business development transactions, operations, manufacturing, and clinical trials. Most recently, he served as regional general counsel for Amgen’s commercial business in Canada, Latin America, the Middle East, and Africa. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-appointment-eric-groen-general?utm_source=openai))
Genelux, headquartered in Westlake Village, California, focuses on developing oncolytic immunotherapies for aggressive solid tumors. The company’s lead product candidate, Olvi-Vec, is currently undergoing Phase 3 clinical trials for the treatment of platinum-resistant/refractory ovarian cancer. ([quiverquant.com](https://www.quiverquant.com/news/Genelux%2BCorporation%2BAppoints%2BEric%2BGroen%2Bas%2BGeneral%2BCounsel%2Band%2BHead%2Bof%2BBusiness%2BDevelopment?utm_source=openai))
As part of his appointment, Groen received a stock option inducement award to purchase 270,000 shares of common stock at an exercise price of $2.83 per share. ([quiverquant.com](https://www.quiverquant.com/news/Genelux%2BCorporation%2BAppoints%2BEric%2BGroen%2Bas%2BGeneral%2BCounsel%2Band%2BHead%2Bof%2BBusiness%2BDevelopment?utm_source=openai))
As of July 7, 2025, Genelux’s stock (NASDAQ: GNLX) is trading at $2.93 per share, reflecting a slight decrease of 1.68% from the previous close.
Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development, effective July 1, 2025. Groen transitions to Genelux from Rani Therapeutics, where he served as General Counsel since September 2021. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-appointment-eric-groen-general?utm_source=openai))
Prior to his tenure at Rani Therapeutics, Groen spent nearly two decades at Amgen, holding various domestic and international legal positions. His roles included leading legal teams responsible for business development transactions, operations, manufacturing, and clinical trials. Most recently, he served as regional general counsel for Amgen’s commercial business in Canada, Latin America, the Middle East, and Africa. ([ir.ranitherapeutics.com](https://ir.ranitherapeutics.com/news-releases/news-release-details/rani-therapeutics-announces-appointment-eric-groen-general?utm_source=openai))
Genelux, headquartered in Westlake Village, California, focuses on developing oncolytic immunotherapies for aggressive solid tumors. The company’s lead product candidate, Olvi-Vec, is currently undergoing Phase 3 clinical trials for the treatment of platinum-resistant/refractory ovarian cancer. ([quiverquant.com](https://www.quiverquant.com/news/Genelux%2BCorporation%2BAppoints%2BEric%2BGroen%2Bas%2BGeneral%2BCounsel%2Band%2BHead%2Bof%2BBusiness%2BDevelopment?utm_source=openai))
As part of his appointment, Groen received a stock option inducement award to purchase 270,000 shares of common stock at an exercise price of $2.83 per share. ([quiverquant.com](https://www.quiverquant.com/news/Genelux%2BCorporation%2BAppoints%2BEric%2BGroen%2Bas%2BGeneral%2BCounsel%2Band%2BHead%2Bof%2BBusiness%2BDevelopment?utm_source=openai))
As of July 7, 2025, Genelux’s stock (NASDAQ: GNLX) is trading at $2.93 per share, reflecting a slight decrease of 1.68% from the previous close.